The binding affinities of spiperone and 3-N-(2-fluoroethyl)spiperone (FESP) have been com pared for several rodent brain receptor sites and for in hibition of monoamine release and uptake sites. FESP and spiperone have almost identical profiles, namely a high affinity for dopamine-D2 and serotonin-S2 receptors,
Since the pioneering work of Wagner et aI. (1983) , N-alkyl derivatives of spiperone are largely used for "in vivo" studies of human dopaminergic D2 and more recently serotonin-5HT2 receptors with positron emission tomography (PET). Accord ing to available evidence (Barrio et aI., 1986; Coenen et al., 1988; Huang et aI., 1989) , eSF]3-N (2-fluoroethyl)spiperone (FESP) appears to be promising and has been recently applied to clinical studies (Wienhard et aI., 1989) . Although the affin ity of FESP for dopamine receptors has been re ported to be close to that of spiperone (Kiesewetter et aI., 1986; Welch et aI., 1988) , so far as we know a determination of the comparative profiles of phar macological activity of these two compounds has not been performed. In the present work, the affin ities of spiperone and FESP for several brain recep tor sites and for inhibition of monoamine release and uptake sites have been compared. The results show that FESP and spiperone have almost identi-a low affinity for a t -adrenergic receptors, and negligible binding to other sites. These results suggest that available data on spiperone binding may be applied to the interpre tation of PET data obtained with FESP. Key Words: Pos itron-Spiperone-Dopamine receptors-Serotonin re ceptors.
cal profiles, namely a high affinity for dopamine-D2 and serotonin-5HT2 receptors, a low affinity for a1adrenergic receptors, and negligible or almost neg ligible binding to other binding sites, suggesting that the large body of pharmacological information on spiperone binding can be applied to the interpreta tion of PET data generated with FESP.
METHODS
3-N-(2-fluoroethyl)spiperone (FESP) was prepared by reaction of spiperone with 1,2-fluorotosylethane, follow ing the synthetic route for the preparation of the radioac tive molecule, using an adaptation of the method of Block et al. (1988) . Briefly, spiperone (40.0 mg, 0.1 mmol) was reacted with 1,2-fluorotosylethane (22.0 mg, 0.1 mmol) , potassium carbonate (69.0 mg, 0.5 mmol), and Kryptofix 2.2.2. (38.0 mg, 0.1 mmol) in 2.0 ml of acetonitrile at 8SOC for 15.0 h. Following evaporation under reduced pres sure, the mixture was fractionated on silica gel (ethanol with 1% NH40H/benzene, 119) yielding 24 mg of 3-N-(2-fluoroethyl)spiperone, which was further purified using HPLC (RP-18 S-P; methanol/H20, 7/3, 0.1% tri ethylamine). The structure of FESP was established by t H-NMR analysis, as described (Chi et aI., 1987) .
The affinities of spiperone and FESP for the various receptors and uptake systems were assayed in inhibition reactions of the specific tritiated ligands. All experiments were carried out with membranes from specific brain re gions from rat or guinea pig, as indicated in Table 1 . IC50 values were determined graphically from the inhibition curves and transformed into Ki values using the Cheng- Prusoff formula. Results were expressed as pIC50 (i.e., -log IC50 in nmol) and K; ± standard deviations (SD). The conditions for the various assays have been extensively validated before and are described in detail in Leysen et al. (1988) .
RESULTS AND DISCUSSION
The pIeso and Kj values calculated in various dis placement reactions carried out on rat or guinea pig brain membranes with spiperone and FESP are summarized in Table 1 . It is apparent from the com parison of the pharmacological profiles of spiperone and FESP that both compounds bind with high af finity to dopamine-D2 receptors and, with a slightly lesser affinity, to the serotonin-5HT 2 receptor. They also have some affinity, although nearly two orders of magnitude lower, for acadrenergic recep tors. The binding of spiperone and FESP to other receptors and release and uptake sites is much lower, probably negligible.
Spiperone is one of the best characterized ligand for dopamine-D2 and serotonin-5HT2 receptors in the brain (Ley sen et al., 1978) . Its fluoroalkyl de rivatives are increasingly popular probes for PET studies of dopaminergic receptors in the striatum and of serotonin-5HT 2 in the frontal cortex (Coenen et aI., 1988; Welch et aI., 1988; Huang et aI., 1989; Jovkar et aI., 1989; Wienhard et aI., 1989) . The present data are a complement to previous pharma cological studies on FESP and clearly demonstrate that the "in vitro" pharmacological profiles of spi perone and FESP are similar, at least within the limits of resolution of "in vitro" binding assays. The affinity of FESP for D2 receptors is comparable to that of N-3-[18F]fluoropropyl)spiperone (Welch et aI., 1988) . The binding properties of FESP appear to be very similar to those of 3-N-methylspiperone (NMSP) studied by Lyon et aI. (1986) . It is worth noting that, in the latter study, there was no signif icant difference in the binding of NMSP to rat and human tissues, suggesting that our rodent data will apply equally to human material. "In vivo" studies with PET have shown that FESP binds with high selectivity and affinity to striatal dopamine-D2 bind ing sites, in the normal brain as well as in patholog ical conditions (Wienhard et aI., 1989) . FESP has also been proposed as an "in vivo" ligand for the serotonin-5HT 2 receptor (Jovkar et aI., 1989) . How ever, the "in vivo" binding of FESP to baboon frontal cortex, an area with high concentrations of serotonin-5HT 2 receptors, is lower than that of flu oropropylspiperone (FPSP) and it would be inter esting to know whether this difference is due to different affinities of FPSP, FESP, and spiperone for serotonin-S2 sites or to another reason. It is well known that "in vitro" binding data are insufficient to validate the use of a receptor ligand "in vivo," and that several factors in addition to "in vitro" binding parameters influence "in vivo" binding. However, the present binding data suggest that FESP can be considered to be as specific as spi perone for dopamine-D2 and serotonin-5HT2 recep tors, and that extraneous binding reflects only non specific binding.
